Ukwelapha i-HIV no-Genvoya

I-Genvoya yi-single-tablet, i-dose fixed-dose inhlanganisela yezidakamizwa ezisetshenziselwa ukwelashwa kwe-HIV, equkethe izidakamizwa ezine ezidambisigciwane :

I-Genvoya iyiphilisi yokuqala yokuhlanganiswa ukusebenzisa i-TAF, inguqulo ephuthumayo ye-tenofovir disoproxil fumarate (TDF) etholakala kwizidakamizwa i-Truvada, i-Atripla ne-Complera.

Njengalokhu, kungabhekwa njengokuthuthukiswa ku- Stribild , ukubunjwa okukodwa kwethebhulethi kuqukethe i-elvitegravir + cobicistat + emtricitabine + TDF.

I-TAF ibhekwa njengephakeme kune-TDF njengoba ikwazi ukuletha izidakamizwa ezisebenzayo ngokuphumelelayo emaqenjini nakwezinye izilinganiso ezincane-okusho ukuthi kunokwakhiwa okuncane kwesidakamizwa egazini kanye nethuba eliphansi kakhulu lokuthuthukisa izinso ezihlobene nezidakamizwa izidakamizwa.

(Nakuba ubungozi be-TDF obuhlobene ne-kidney toxicity bubhekwa njengamazwe asethuthukile, leyo ngozi ibonakala ikhula kakhulu emazweni asathuthuka lapho kunomthelela omkhulu wezifo ezingasebenzi ngaphambili.)

Isiqondiso Sokwelapha

UGenvoya wamukelwa yi-US Food Administration and Drug Administration ngoNovemba 5, 2015, ukuze kusetshenziswe kokubili abadala nabantwana abangaphezu kweminyaka engu-12 abangakaze babe ne-HIV yokwelapha futhi banesisindo esingaphezu kuka-77 lbs (35 kgs). Iphinde ivunyelwe abantu abadala ekuhlinzekeni okwelapha okungaqondakali (okungabonakali).

Ukubunjwa

I-Genvoya iyithebhulethi eluhlaza, ene-oblong, elinefilimu, enama-150mg we-elvitegravir, ama-150mg we-cobicistat, 200mg we-emtricitabine no-10mg we-TAF. Ihlanganiswe ne "GSI" ngakolunye uhlangothi futhi "510" ngakolunye uhlangothi.

Isilinganiso

Ithebhulethi eyodwa ithathwa nsuku zonke ngokudla. I-Genvoya akufanele ithathwe nganoma yimuphi omunye umuthi we-antiretroviral osetshenziselwa ukuphatha i-HIV.

Okuqhamuka uma udla imishanguzo

Imithi eminye yemiphumela emibi iye yaphawulwa ezigamekweni zokuhlolwa komtholampilo ezithatha iGenvoya. Izenzakalo ezivame kakhulu, ezibikwe ku-5% noma ngaphezulu kweziguli, ziyi:

Imiphumela emibi yayivamile, ixazululwa ngaphezu kweviki 1-2, kanti iziguli ezimbalwa ziyayeka ngenxa yokungabekezelelani kwelashwa.

Ukungafani

U-Genvoya akufanele athathwe ngezidakamizwa noma izithako ezilandelayo:

Imithi ye-Anti-migraine: I-Cafergot, i-Migergot, i-Ergostat, i- Ergotamine ye-Medihaler, i- Wigraine, i-Wigrettes, i- Ergotrate, i-Methergine, i-DHE 45

Okunye okucatshangwayo

I-Genvoya ayinconywa ngeziguli ezinokukhubazeka kwezinso (ezichazwe njengokuthi imvume yokudalulwa kwama-creinine engaphansi kuka-30mL ngomzuzu). Sicela ukutshela udokotela wakho uma ukhona noma ulashwa nganoma yisiphi isifo sezinso somunye udokotela.

I-Genvoya ayinconywa ngeziguli ezinokukhubazeka kwesibindi noma kulabo abanesifo sengculaza esingapheli nesifo se- hepatitis B (HBV) ngoba singabangela kakhulu izinkinga zesibindi. Kunconywa ukuthi abantu abane-HIV bahlolwe i-HBV ngaphambi kokubeka iGenvoya. Sicela utshele udokotela wakho uma unezinkinga zesibindi kanye / noma umlando we-hepatitis.

Imithombo:

Ukuphathwa kwe-US nokuDrug. "I-FDA ivumela ukwelashwa okusha kwe-HIV." I-Silver Spring, e-Maryland; ukushicilelwa okukhishwe ngo-Novemba 5, 2015.

I-Sciences yaseGileyadi. "I-Genvoya - Amaphuzu avelele okuchaza ulwazi." Foster City, California